Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a <scp>Genome‐Wide</scp> Association <scp>Meta‐Analysis</scp> Followed by Mendelian Randomization
In this study, we aimed to establish the causal effects of lowering sclerostin, target of the antiosteoporosis drug romosozumab, on atherosclerosis and its risk factors.
-д хадгалсан:
Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Формат: | Revisão |
Хэл сонгох: | англи |
Хэвлэсэн: |
2023
|
Онлайн хандалт: | https://doi.org/10.1002/art.42538 |
Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|